Copertina

The potential adverse effects of hypodermic glucagon‐like peptide ‐1 receptor agonist on patients with type 2 diabetes: A population‐based study

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Zhiyuan Cheng, Shuang Wang, Fu‐rong Li, Cheng Jin, Chunbao Mo, Jing Zheng, Xia Li, Fengchao Liang, Jinkui Yang, Dongfeng Gu
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	Journal of Diabetes
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Impact of glucagon‐like peptide‐1 receptor agonists on the incidence of inflammatory bowel disease in people with type 2 diabetes
di: Fu‐Shun Yen, et al.
Pubblicazione: (2025)

Association of glucagon‐like peptide‐1 receptor agonist use with clinical outcomes in patients with rheumatoid arthritis and type 2 diabetes
di: Yu‐Ting Yu, et al.
Pubblicazione: (2026)

Trends in obesity and glucagon‐like peptide‐1 receptor agonist prescriptions in type 1 diabetes in the United States
di: Yunwen Xu, et al.
Pubblicazione: (2025)

Unintentional periconceptional exposure to glucagon‐like peptide‐1 receptor agonists and adverse pregnancy outcomes: A nationwide cohort study in Taiwan
di: Yi‐Chang Chou, et al.
Pubblicazione: (2025)

Risks of peri‐ and postoperative complications with glucagon‐like peptide‐1 receptor agonists
di: David C. Klonoff, et al.
Pubblicazione: (2024)

Suicidality among users of glucagon‐like peptide‐1 receptor agonists: An emerging signal?
di: Darren Lau, et al.
Pubblicazione: (2024)

Orforglipron, an oral non‐peptide glucagon‐like peptide‐1 receptor agonist, improves markers of β‐cell function and insulin sensitivity in type 2 diabetes
di: Julio Rosenstock, et al.
Pubblicazione: (2025)

Reply: Time‐Related Biases in Observational Studies of GLP ‐1 Agonists and Cancer Risk
di: Zhiyuan Cheng, et al.
Pubblicazione: (2026)

The effect of glucagon‐like peptide‐1 receptor agonists on cardiac function and structure in patients with or without type 2 diabetes mellitus: An updated systematic review and meta‐analysis
di: Yu Zhang, et al.
Pubblicazione: (2024)

Use of continuous glucose monitoring when initiating glucagon‐like peptide ‐ 1 receptor agonist therapy in insulin‐treated diabetes
di: Irl B. Hirsch, et al.
Pubblicazione: (2024)

Comparative effectiveness of insulin glargine, glucagon‐like peptide‐1 receptor agonists and sodium‐glucose cotransporter‐2 inhibitors in veterans with type 2 diabetes
di: Jincheng Shen, et al.
Pubblicazione: (2025)

Incidence and progression of diabetic retinopathy in patients treated with glucagon‐like peptide‐1 receptor agonists versus sodium‐glucose cotransporter 2 inhibitors: A population‐based cohort study
di: Donna Shu‐Han Lin, et al.
Pubblicazione: (2024)

A long‐acting glucose‐dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon‐like peptide‐1 receptor agonist therapy
di: Filip K. Knop, et al.
Pubblicazione: (2024)

Potential role of glucagon like peptide (GLP)‐1 receptor agonist to reduce risk of colorectal cancer?
di: Iskandar Idris
Pubblicazione: (2024)

Characterisation of real‐world patients who discontinued a glucagon‐like peptide‐1 agonist
di: Jessica Van Laren, et al.
Pubblicazione: (2026)

Getting the measure of the pressure: Optimal assessment of the effects of glucagon‐like peptide‐1 receptor agonists on blood pressure
di: Karen L. Jones, et al.
Pubblicazione: (2024)

One step closer to solving the mystery of the anti‐inflammatory effects of glucagon‐like peptide‐1 receptor agonists
di: Hirotaka Watada
Pubblicazione: (2024)

Real‐world use of glucagon‐like peptide‐1 receptor agonists in youth with type 2 diabetes is associated with short‐term improvements in HbA1c
di: Stephanie L. Samuels, et al.
Pubblicazione: (2024)

Long‐term safety and efficacy of glucagon‐like peptide‐1 receptor agonists in individuals with obesity and without type 2 diabetes: A global retrospective cohort study
di: Yu‐Nan Huang, et al.
Pubblicazione: (2024)

Current treatment guidelines and glycated haemoglobin goals for type 2 diabetes: Which patients are most likely to benefit from fixed‐ratio basal insulin glucagon‐like peptide‐1 receptor agonist combinations?
di: Kevin Cowart, et al.
Pubblicazione: (2025)

Efficacy and safety of glucagon‐like peptide 1 receptor agonists across all health outcomes in type 2 diabetes: An umbrella review and evidence map of randomised controlled trials
di: Dongjin Yeo, et al.
Pubblicazione: (2025)

Correction to “Long‐term safety and efficacy of glucagon‐like peptide‐1 receptor agonists in individuals with obesity and without type 2 diabetes: A global retrospective cohort study”
Pubblicazione: (2025)

Geographic variation in sodium‐glucose cotransporter 2 inhibitor and glucagon‐like peptide‐1 receptor agonist use in people with type 2 diabetes in New South Wales, Australia
di: Juliana de Oliveira Costa, et al.
Pubblicazione: (2024)

Characterizing body composition modifying effects of a glucagon‐like peptide 1 receptor‐based agonist: A meta‐analysis
di: Ruoyang Jiao, et al.
Pubblicazione: (2024)

Association between glucagon‐like peptide ‐1 receptor agonists and risk of suicidality: A comprehensive analysis of the global pharmacovigilance database
di: Tae Hyeon Kim, et al.
Pubblicazione: (2024)

Adverse event comparison between glucagon‐like peptide‐1 receptor agonists and other antiobesity medications following bariatric surgery
di: Jason M. Samuels, et al.
Pubblicazione: (2024)

Effect of preceding drug therapy on the renal and cardiovascular outcomes of combined sodium‐glucose cotransporter‐2 inhibitor and glucagon‐like peptide ‐1 receptor agonist treatment in patients with type 2 diabetes and chronic kidney disease
di: Shunichiro Tsukamoto, et al.
Pubblicazione: (2024)

Glucagon‐like peptide‐1 receptor agonists and kidney outcomes
di: Richard J. MacIsaac, et al.
Pubblicazione: (2024)

Evaluation of an oral small‐molecule glucagon‐like peptide‐1 receptor agonist, lotiglipron, for type 2 diabetes and obesity: A dose‐ranging, phase 2, randomized, placebo‐controlled study
di: Neeta B. Amin, et al.
Pubblicazione: (2024)

Unexpected cardiovascular risks of glucagon‐like peptide‐1 receptor agonist and aspirin co‐administration in individuals with obesity, with and without type 2 diabetes: A propensity score matched cohort study
di: Chia‐Ming Lin, et al.
Pubblicazione: (2025)

Practical limitations of complex insulin therapies in type 2 diabetes: Focus on therapy simplification using fixed‐ratio combinations of basal insulin and a glucagon‐like peptide‐1 receptor agonist
di: Luděk Horváth, et al.
Pubblicazione: (2025)

Treatment intensification following glucagon‐like peptide‐1 receptor agonists in type 2 diabetes: Comparative effectiveness analyses between different basal insulins. RESTORE ‐G real‐world study
di: Raffaele Napoli, et al.
Pubblicazione: (2024)

Medication adherence to sodium‐glucose cotransporter‐2 inhibitors versus glucagon‐like peptide‐1 receptor agonists: A meta‐analysis
di: Conner E. Johnson, et al.
Pubblicazione: (2024)

Cardiovascular risk reduction with glucagon‐like peptide‐1 receptor agonists is proportional to HbA1c lowering in type 2 diabetes: An updated meta‐regression analysis incorporating FLOW and SOUL trials
di: Masashi Hasebe, et al.
Pubblicazione: (2025)

Effects of glucagon‐like peptide‐1 receptor agonists on glycated haemoglobin and continuous glucose monitoring metrics as adjunctive therapy to insulin in adults with type 1 diabetes: A meta‐analysis of randomized controlled trials
di: Paschalis Karakasis, et al.
Pubblicazione: (2024)

The influence of the glucagon‐like peptide‐1 receptor agonist, liraglutide, on dietary patterns and nutrient intakes in patients with obesity and prediabetes: A secondary analysis of a randomized controlled trial
di: Kelli M. Richardson, et al.
Pubblicazione: (2025)

Efficacy of glucagon‐like peptide‐1 receptor analogues in kidney transplant recipients with diabetes: A single‐centre retrospective study
di: Katie Mei, et al.
Pubblicazione: (2026)

Risk of thyroid cancer related to glucagon‐like peptide‐1 receptor agonists: A systematic review with meta‐analysis of harms of randomized controlled trials
di: Lucas Duchemin, et al.
Pubblicazione: (2025)

Once‐daily oral small‐molecule glucagon‐like peptide‐1 receptor agonist lotiglipron (PF‐07081532) for type 2 diabetes and obesity: Two randomized, placebo‐controlled, multiple‐ascending‐dose Phase 1 studies
di: Clare Buckeridge, et al.
Pubblicazione: (2024)

Tirzepatide, a dual glucose‐dependent insulinotropic polypeptide/glucagon‐like peptide 1 receptor agonist, exhibits favourable effects on pancreatic β‐cells and hepatic steatosis in obese type 2 diabetic db/db mice
di: Yuichiro Iwamoto, et al.
Pubblicazione: (2024)